ChemoCentryx, Inc. (CCXI)
(Delayed Data from NSDQ)
$12.93 USD
+0.14 (1.09%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.93 USD
+0.14 (1.09%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
by Zacks Equity Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
by Zacks Equity Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -21.74% and 11.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.
ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
by Zacks Equity Research
ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
by Zacks Equity Research
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.